Using blood tests to tailor treatment for lymphoma patients
Official title: Circulating tumor DNA guided de-escalation of frontline diffuse large B-cell lymphoma therapy
Funded at Columbia University Health Sciences · NIH-11045782 · Data updated 2026-11-12
This study is looking at how a simple blood test can help doctors tailor treatment for people newly diagnosed with diffuse large B-cell lymphoma, so they can get the right amount of therapy to reduce side effects while still being effective.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $82,250 |
| NIH project number | 5R03CA286676-02 |
| Project ID | NIH-11045782 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with newly diagnosed diffuse large B-cell lymphoma who are at an advanced stage and may be eligible for treatment de-escalation based on ctDNA analysis.
✕Less likely to help
Patients with early-stage DLBCL or those who do not have detectable ctDNA may not benefit from this research.
What this research studies
This research investigates how circulating tumor DNA (ctDNA) can be used to guide the treatment of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). By analyzing ctDNA from blood samples, the study aims to identify patients who may benefit from a reduced treatment regimen, potentially decreasing side effects while maintaining effectiveness. The approach involves real-time assessment of molecular responses to therapy, which could lead to more personalized treatment plans. This innovative method seeks to improve patient outcomes by allowing for treatment de-escalation based on individual responses.
Why it matters
Potential benefit: If successful, this research could lead to less intensive treatment for some lymphoma patients, reducing side effects while maintaining effective cancer control.
How similar studies have gone: While the use of ctDNA in DLBCL has shown promise in retrospective studies, this approach of real-time assessment for treatment de-escalation is novel and has not been extensively tested.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Cherng, Hua-Jay Jeffery — Columbia University Health Sciences
- Study coordinator: Cherng, Hua-Jay Jeffery
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.